Senescence-associated pathways in osteoarthritic chondrocytes

Senescence-associated pathways in osteoarthritic chondrocytes refer to the complex signaling networks and phenotypic changes that occur when cartilage cells enter a state of permanent cell cycle arrest. These pathways are primarily driven by the activation of the p16INK4a/Rb and p53/p21 tumor suppressor axes in response to stressors like mechanical injury or oxidative stress (Coryell et al., 2021, Nature Reviews Rheumatology). A hallmark of these pathways is the development of a Senescence-Associated Secretory Phenotype (SASP), where chondrocytes secrete high levels of pro-inflammatory cytokines (e.g., IL-6) and matrix-degrading enzymes (e.g., MMP-13), leading to the breakdown of the articular cartilage (Loeser et al., 2016, Arthritis & Rheumatology). In osteoarthritis, the accumulation of these senescent cells creates a self-perpetuating cycle of inflammation and tissue degradation (Jeon et al., 2017, Nature Medicine). Therapeutic strategies targeting these pathways include senolytics, which selectively induce apoptosis in senescent cells by targeting anti-apoptotic proteins like BCL-2, and senomorphics, which aim to suppress the harmful SASP (Kirkland & Tchkonia, 2020, JAMA). While targeting these pathways offers a potential disease-modifying approach for osteoarthritis, challenges include ensuring the selective elimination of senescent cells without affecting normal physiological processes such as tissue repair and wound healing.

Other names

Chondrocyte senescenceSenescence-associated secretory phenotype in osteoarthritisCellular senescence in osteoarthritisSASP in OA chondrocytes

Senolytics selectively eliminate senescent cells by inhibiting pro-survival pathways (e.g., BCL-2 family, MDM2/p53), while senomorphics inhibit the senescence-associated secretory phenotype (SASP) without inducing cell death (Kirkland & Tchkonia, 2020, JAMA).